Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure.

These differences were highly significant ( P < 0.0001 by anova ).

also in 132,142 other papers

In studies that allowed sulfonylureas (and metformin) as background medication (indicated by a light grey background area) 18,55,56 , this unique advantage of incretin mimetics was lost, although a weak trend towards less hypoglycemia remained.

also in 1,404 other papers